Resmed (RMD) Stock
Sleep apnea device giant with digital health services. Here's the price, business snapshot, and what's worth knowing about Resmed in August 2026.
ResMed Inc. (RMD) is a global medical‑technology company best known for devices that treat sleep apnoea, chronic obstructive pulmonary disease (COPD) and other respiratory conditions. It sells CPAP machines, masks, ventilators and a growing suite of cloud-connected software and services aimed at long‑term patient management. Revenue mixes device sales, consumables and recurring digital subscriptions — a model that can support predictable cash flow as the installed base and mask/consumable replacements continue. Key attractions for investors include an ageing population, steady demand for sleep solutions, and ResMed’s push into remote-monitoring and digital health. Risks include reimbursement changes, competition from other device makers, supply‑chain pressures and regulatory approvals; performance can vary and past results do not guarantee future returns. Market cap is about $39.1bn, making it a large-cap healthcare name. This is general educational information, not personalised advice — consider your personal circumstances and tolerance for volatility before investing.
Why It’s Moving
ResMed is catching analyst attention as updated price targets keep the stock in focus.
- RBC Capital lifted its price objective to $244 while keeping a cautious stance, signaling that analysts still see upside but remain selective on the name.
- Recent analyst notes have been mixed, with some firms maintaining positive ratings and others trimming targets, which has kept sentiment from turning decisively bullish.
- The broader analyst consensus remains split between upside potential and valuation caution, so the stock is being driven more by rating changes than by a fresh company-specific catalyst.
ResMed is catching analyst attention as updated price targets keep the stock in focus.
- RBC Capital lifted its price objective to $244 while keeping a cautious stance, signaling that analysts still see upside but remain selective on the name.
- Recent analyst notes have been mixed, with some firms maintaining positive ratings and others trimming targets, which has kept sentiment from turning decisively bullish.
- The broader analyst consensus remains split between upside potential and valuation caution, so the stock is being driven more by rating changes than by a fresh company-specific catalyst.
About This Stock
RESMED INC
RMD
Current Price
$229.85
Potential 12 Month Profit
5.54%
Sector
Healthcare
Industry
Healthcare Equipment & Supplies
Ticker
RMD
Market Cap
$33.27B
Potential 12 Month Profit
5.54%
Sector
Healthcare
Industry
Healthcare Equipment & Supplies
Sixth Month Growth Performance
When is the next earnings date for RESMED INC (RMD)?
ResMed’s next earnings date is expected to be Thursday, October 29, 2026. It will cover fiscal first-quarter 2027 results. The company has not formally confirmed the date yet, but this timing matches its usual quarterly reporting pattern.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ResMed's stock, indicating expected growth towards a higher target price.
Financial Health
ResMed is performing well with strong revenue and cash flow, indicating good financial stability.
Dividend
ResMed's dividend yield of 0.92% is below average, which may not appeal to dividend-seeking investors. If you invested $1000 you would be paid $9.20 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Recurring revenue model
ResMed’s mix of devices plus consumables and subscriptions can create steadier cash flows, though revenues still face reimbursement and demand risks.
Global patient base
An ageing population and rising diagnosis of sleep disorders support long-term demand, but regional regulation and payor policies can affect growth.
Connected‑care push
Investment in cloud platforms and remote monitoring could boost stickiness and services revenue, yet technology adoption and competition may vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.